Company news

PharmaEssentia Corp. news in 2026

PharmaEssentia Corp.'s news releases, calls and decks from 2026, newest first.

View company

PharmaEssentia to Present at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

September 9, 2026

FDA Approves PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) for Adults with Essential Thrombocythemia, A Rare Blood Cancer

August 31, 2026

PharmaEssentia Announces Health Canada Approval of BESREMi(R) (ropeginterferon alfa-2b) for Polycythemia Vera (PV)

July 7, 2026

PharmaEssentia Announces Health Canada Approval of BESREMi® (ropeginterferon alfa-2b) for Polycythemia Vera (PV)

July 6, 2026

PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen (ropeginterferon alfa-2b-njft) for Polycythemia Vera

June 29, 2026

PharmaEssentia Expands North American Commercial Footprint with Acquisition of Canadian Partner FORUS Therapeutics

June 11, 2026

PharmaEssentia Announces Taiwan Approval of BESREMi® for Essential Thrombocythemia, Marking First Global Approval in ET

June 10, 2026

PharmaEssentia Appoints Eric Vogel as U.S. Head of Commercialization Ahead of Potential Launch of BESREMi® in Essential Thrombocythemia

May 27, 2026

PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026

May 22, 2026

Taiwan's Representative to the United States Alexander Tah-ray Yui Visits PharmaEssentia's Puerto Rico Facility Alongside Puerto Rico Officials

April 27, 2026

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health

April 24, 2026

PharmaEssentia Signs Investment Agreement for New Manufacturing Facility in Puerto Rico

April 2, 2026

PharmaEssentia Announces Japan Approval of High-Dose Dosing Regimen for BESREMi®

March 2, 2026

PharmaEssentia Announces Plans to Establish New U.S. Manufacturing Facility in Puerto Rico to Support Global Growth of BESREMi®

February 9, 2026

PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for Treatment of Essential Thrombocythemia (ET)

January 27, 2026

FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)

January 13, 2026

PharmaEssentia Announces Positive Topline Phase 2b Data from EXCEED-ET Study Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia

January 12, 2026

Decks in 2026